Descripción Del Producto

Wegovy 1Mg

Wegovy 1mg is a prescription medication containing semaglutide, a GLP-1 receptor agonist originally developed for type 2 diabetes (as Ozempic) but approved by the FDA in 2021 for chronic weight management. It’s intended for adults with obesity (BMI ≥30) or overweight (BMI ≥27) who have at least one weight-related condition, such as high blood pressure, type 2 diabetes, or high cholesterol. It works by mimicking a hormone that regulates appetite and blood sugar, leading to reduced hunger and calorie intake.

Dosage Information

Wegovy is administered as a once-weekly subcutaneous injection. The dosing schedule starts low and titrates up to minimize side effects:

• Initial dose: 0.25 mg weekly for 4 weeks.
• Escalation: Increases to 0.5 mg, then 1 mg, 1.7 mg, and up to 2.4 mg weekly, based on tolerance.
• 1 mg dose: This is typically reached after about 8-12 weeks of treatment. It’s not the starting dose but a maintenance level for many patients. Always follow your doctor’s prescription, as individual dosing varies.

The 1 mg strength is available in pre-filled pens for easy self-injection.

How It Works

Semaglutide slows gastric emptying, reduces appetite, and promotes satiety. Clinical trials (like the STEP program) showed average weight loss of 15-20% of body weight over 68 weeks when combined with diet and exercise. It’s not a quick fix; lifestyle changes are essential for long-term success.

Side Effects and Precautions

Common side effects include nausea, vomiting, diarrhea, constipation, and abdominal pain (often mild and temporary). Serious risks include pancreatitis, kidney issues, or thyroid tumors (rare). It’s contraindicated in people with a history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2.

Consult a healthcare provider before starting, especially if you have diabetes, heart disease, or are pregnant/breastfeeding. Wegovy isn’t for cosmetic weight loss and requires monitoring.